Clinical impact of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in patients with resectable pancreatic cancer: diagnosing lymph node metastasis and predicting survival

摘要

PurposeTo evaluate the diagnostic accuracy of fluorine-18-fluorodeoxyglucose PET/computed tomography (F-18-FDG PET/CT) for lymph node (LN) metastasis and the prognostic significance of F-18-FDG PET/CT LN parameters in patients with resectable pancreatic cancer.Patients and methodsPatients with resectable pancreatic cancer who underwent staging F-18-FDG PET/CT between May 2007 and September 2016 were retrospectively enrolled and analyzed through medical record and image re-evaluation. The diagnostic accuracy of F-18-FDG PET/CT in predicting LN metastasis was evaluated and compared with that of contrast-enhanced abdominal computed tomography (CECT). Prognostic variables, including LN parameters assessed by F-18-FDG PET/CT [standardized uptake value (SUV)(LN) and LN/tumor SUV ratio], that affect disease-free survival (DFS) and overall survival (OS) were evaluated by regression analysis.ResultsWhen predicting LN metastasis, F-18-FDG PET/CT showed greater sensitivity, positive predictive value, negative predictive value, and accuracy than CECT. Among prognostic factors affecting DFS, PET-positive LN (P=0.008), and LN/tumor SUV ratio (P=0.003) were found to be significant by regression analysis. Among the variables affecting OS, lymphovascular invasion (P=0.018) and the LN/tumor SUV ratio (P=0.046) were found to be significant.Conclusion(18)F-FDG PET/CT showed higher diagnostic accuracy in predicting LN metastasis than CECT in patients with resectable pancreatic cancer. Only the LN/tumor SUV ratio of F-18-FDG PET/CT was an independent prognostic variable in both DFS and OS.